Chemical Nametazemetostat
Dosage FormTablet (oral; 200 mg)
Drug ClassInhibitors
SystemMusculoskeletal, Skin
Approval Year2020


  • Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Last updated on 10/19/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tazverik (tazemetostat) Prescribing Information2020Epizyme Inc., Cambridge, MA